Skip to content
Catalyst

PapersPMID:40795809

Azithromycin for Prevention of Bronchopulmonary Dysplasia and Other Neonatal Adverse Outcomes in Preterm Infants: An Updated Systematic Review and Meta-Analysis.

Neonatology2026The record ↗

  1. Finding, very limited evidenceno difference foundDuration of mechanical ventilation

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “The composite of BPD or death (RR: 0.95; 95% CI: 0.83-1.10; p = 0.53; I2 = 50.2%), BPD (RR: 0.98; 95% CI: 0.83-1.15; p = 0.77; I2 = 38.1%), death (RR: 0.88; 95% CI: 0.66-1.19; p = 0.41; I2 = 0%), NEC (RR: 0.94; 95% CI: 0.69-1.26; p = 0.67; I2 = 0%), IVH (RR: 1.22; 95% CI: 0.89-1.68; p = 0.22; I2 = 3.5%), RoP (RR: 1.35; 95% CI: 0.43-4.28; p = 0.61; I2 = 76.3%), duration of mechanical ventilation (MD: 0.13; 95% CI: -1.35 to 1.60; p = 0.87; I2 = 0%), and postnatal corticosteroid requirement (RR: 0.84; 95% CI: 0.64-1.08; p = 0.18; I2 = 34.5%) were similar between the groups.”
    Study
    meta-analysis
    Effect
    0.13 mean difference, 95% CI −1.35 to 1.6
    Population
    preterm infants (meta-analysis of 6 RCTs, 1,360 infants; azithromycin vs placebo, whole population not restricted by Ureaplasma status)

Study record

Design
meta-analysis
Species
human
Population
preterm infants
Participants
1,360
Comparator
placebo
Duration
not reported
Endpoints measured
8